1025814-13-4

N-(2-Chloro-6-methylphenyl)-2-[[6-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-2-methyl-4-pyrimidinyl]amino]- 5-thiazolecarboxamide is an impurity in the preparation of Dasatinib (D193600), a new, oral, small-molecule Tyrosine Kinase Inhibitor (TKI) for the treatment of CML. Antineoplastic. It is a COVID19-related research product.